TAKEDA Aktie

 

JPM issued a research report stating that it lowered the TP for Ascentage Pharma (06855.HK) from HKD93 to HKD89 and maintained an Overweight rating.JPM expects that Takeda Pharmaceutical in Japan will not exercise its exclusive option for olverembatinib before 2027. In addition, the bank assumes that Phase III clinical trial dat......

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment....

Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?...

DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release....

SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it has received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). The decision was driven by strategic considerations and is not related to efficacy or safety data. DNL593 is an investigational progranulin replacement therapy utilizing Denali's Protein TransportVehicle™ (PTV) to deliver progranulin across the blood-brain barrier to the brain for the treatment of frontotemporal dementia-granulin (FTD-GRN). Denali has led development activities and will regain full control of DNL593 and its intellectual property portfolio....

Tokyo, April 3 (Jiji Press)--Liberal Democratic Party members are forming intraparty groups in a bid to expand their sway in the Japanese ruling party, after most of the party's factions disbanded following a slush funds scandal. On Thursday, former internal affairs minister Ryota Takeda held the first meeting of a new study group he heads, in the Diet, the country's parliament. The meet......

TOKYO (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (......

HONG KONG (dpa-AFX) - Takeda (TAK) announced new data from two pivotal Phase 3 studies of zasocitinib (TAK-279), its next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in a......

Board unites senior regulatory, quality, investment, and AI leaders from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford UniversitySAN FRANCISCO--(BUSINESS WIRE)--$TMV #AIinPharma--Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thought leaders with expertise spanning pharma regulatory strategy and operations, health authority policy and practice, capital markets, and academic research, the SAB will serve as a strategic forum to guide the evolution of the Weave Platform and advance the responsible adoption of AI across the life sciences regulatory ecosystem. "Regulatory workflows are the backbone of a therapeutic candidate's success, and for too long they have been defined by manual, time-consuming processes that slow the path from discovery to patients," said Brandon Rice, Co-Founder and CEO of Weave Bio. "Our Strategic Advisory Boar...

Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook...

The US Supreme Court cleared the way for a multibillion-dollar racketeering lawsuit that accuses Takeda Pharmaceutical Co. and Eli Lilly & Co. of marketing the Actos diabetes drug without disclosing its link to bladder cancer....

- Sandoz hat mit Samsung Bioepis seine bereits bestehende Partnerschaft ausgebaut. Aktuell haben die beiden Firmen eine Lizenz-, Entwicklungs- und Vermarktungsvereinbarung für bis zu fünf Biosimilar-Wirkstoffe geschlossen. Als erstes Projekt ist ein Vedolizumab-Biosimilar in früher Entwicklungsphase vorgesehen, basierend auf dem Referenzarzneimittel Entyvio von Takeda zur Behandlung von Morbus Crohn, Colitis ulcerosa oder Pouchitis bei Erwachsenen....

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk....

Tokyo, March 11 (Jiji Press)--Former Japanese interior affairs minister Ryota Takeda was appointed chair of the Japan-South Korea parliamentarians' union, a suprapartisan group of Japanese lawmakers promoting ties between the two countries, on Tuesday. Takeda, a member of the ruling Liberal Democratic Party, succeeded former Prime Minister Yoshihide Suga, an LDP member who has retired from ......

LOS ANGELES, March 6, 2026 /PRNewswire/ -- What is the lawsuit about? A National Third-Party Payor ("TPP") Class has been certified in a class action lawsuit against Defendant Takeda Pharmaceuticals USA, Inc. and its parent company Defendant Takeda Pharmaceutical Company Limited (jointly,......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) and Protagonist Therapeutics, Inc. (PTGX) said Monday the U.S. Food and Drug Administration has accepted the New Drug Application for ......

Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial. Importance Rank:  1 read more...

The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation. Through this arrangement, Takeda will The post Takeda and Iambic announce $1.7bn deal to advance small molecule programmes appeared first on Pharmaceutical Business review....